Pharmaceutical composition of CDKS inhibitor and preparation method therefor

MYPI2025002958A0Undetermined Publication Date: 2024-05-18XUANZHU BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025002958
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-18
Filing Date
2023-11-17
Publication Date
2024-05-18

AI Technical Summary

Technical Problem

Existing CDK4/6 kinase inhibitor drugs have problems with disintegration, dissolution and stability, making it difficult to effectively treat cancers mediated by CDK4/6 kinase.

Method used

Prepare a pharmaceutical composition, including CDK4/6 kinase inhibitors, fillers, binders and disintegrants, and optionally contain lubricants and glidants, and form suitable tablets through specific component ratios and processes. dosage form or capsule to ensure the stability and effective release of the drug.

Benefits of technology

The pharmaceutical composition has good disintegration and dissolution properties, high stability, is suitable for treating cancer mediated by CDK4/6 kinase, and provides a long shelf life and controllable production cost.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

ABSTRACT PHARMACEUTICAL COMPOSITION OF CDKS INHIBITOR AND PREPARATION METHOD THEREFOR A pharmaceutical composition of a CDKs inhibitor compound of formula (I), a preparation method for the pharmaceutical composition, and use of the pharmaceutical composition in the preparation of a drug for treating cancer. The provided pharmaceutical composition is good in performance and has stable properties. The production process for the pharmaceutical composition is robust. The quality of the pharmaceutical composition is stable and controllable. The pharmaceutical composition exhibits strong reproducibility and meets the requirements for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition of CDKs inhibitors and preparation method thereof Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to a composition of a class of CDKs kinase inhibitors, a preparation method of the composition, and use of the composition in preparing a drug for treating cancer. Background Art

[0002] The development of tumors is associated with an imbalance in the expression of multiple oncogenes and tumor suppressor genes. The functional effects of nearly all oncogenes and tumor suppressor genes ultimately converge on the cell cycle. Therefore, tumors can be considered a type of cell cycle disease (CCD), and regulating or blocking the cell cycle is one approach to treating tumors. Currently, many molecules involved in cell cycle regulation have been discovered, among which cyclin-dependent kinases (CDKs) are core components of the cell cycle regulatory network. CDKs, as catalytic subunits, are a class of serine (Ser) / threonine (Thr) kinases that act as important intracellular signaling molecules and participate in different stages of the cell cycle. Research has shown that abnormalities in any link of the cell cycle regulatory network, centered around CDKs, can lead to cell cycle abnormalities and ultimately to tumorigenesis. The CDK family currently consists of 21 subtypes, each of which functions by binding to its regulatory subunits, cyclins. The functions of various CDK subtypes, in addition to affecting the cell cycle, also include regulating transcription, DNA repair, differentiation, and programmed cell death. Based on the key role of CDKs in regulating the proliferation and death of tumor cells, the CDKs kinase family provides opportunities and new areas for the discovery and development of anti-tumor drugs.

[0003] Among the CDKs involved in the cell cycle, CDK4 / 6 plays an irreplaceable role. Cancer-associated cell cycle mutations primarily occur during the G1 and G1 / S phase transitions. The CDK4 / 6 complex with Cyclin D phosphorylates pRb, a product of the tumor suppressor gene Rb, releasing the bound transcription factor E2F, initiating transcription of genes involved in the S phase, prompting cells to pass the checkpoint and transition from G1 to S phase. Approximately 80% of human tumors harbor abnormalities in the cyclin D-CDK4 / 6-INK4-Rb pathway. Alterations in this pathway accelerate G1 phase progression, leading to increased tumor cell proliferation and a survival advantage. Therefore, intervening in this pathway has become a therapeutic strategy, and CDK4 / 6 has become a highly promising anti-tumor target.

[0004] PCT / CN2014 / 095615 discloses the following compound formula (I). Studies have shown that the compound has excellent CDK4 / 6 kinase inhibitory activity and exhibits good blood-brain barrier permeability, providing the possibility of CDKs inhibitors as tumor treatment and having good safety.

[0005] Summary of the Invention

[0006] The present invention provides a pharmaceutical composition of a compound of formula (I) and a method for preparing the same. The technical problem to be solved is to provide a pharmaceutical composition that is suitable for the physicochemical properties of the compound of formula (I) and has good pharmaceutical properties such as disintegration, dissolution, release, and stability. Specifically, the present invention provides a pharmaceutical composition comprising a compound of formula (I), a filler, a binder, and a disintegrant, and optionally, a lubricant and / or a glidant.

[0007] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0008] Wherein, the filler is selected from microcrystalline cellulose / lactose monohydrate or microcrystalline cellulose / pregelatinized starch.

[0009] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0010] Wherein, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate, starch, and dextrin;

[0011] The binder is selected from one or more of copovidone VA64, hydroxypropyl cellulose, povidone K30, sodium carboxymethyl cellulose, methyl cellulose or hypromellose;

[0012] The disintegrant is selected from one or more of cross-linked carboxymethyl cellulose sodium, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose or cross-linked polyvinylpyrrolidone;

[0013] The lubricant is selected from one or more of magnesium stearate, stearic acid, sodium stearyl fumarate, and glyceryl behenate;

[0014] The glidant is selected from silicon dioxide or talc.

[0015] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant,

[0016] Wherein, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, anhydrous calcium hydrogen phosphate, starch, and dextrin;

[0017] The binder is selected from one or more of hydroxypropyl cellulose, povidone K30 or hypromellose;

[0018] The disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate or cross-linked polyvinylpyrrolidone.

[0019] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0020] Wherein, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, anhydrous calcium hydrogen phosphate, starch, and dextrin;

[0021] The binder is selected from one or more of hydroxypropyl cellulose, povidone K30 or hypromellose;

[0022] The disintegrant is selected from one or more of cross-linked carboxymethyl cellulose sodium, sodium starch glycolate or cross-linked polyvinylpyrrolidone;

[0023] The lubricant is selected from one or more of magnesium stearate, stearic acid, and glyceryl behenate;

[0024] The glidant is selected from silicon dioxide or talc.

[0025] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0026] The filler is selected from one or two of microcrystalline cellulose, lactose monohydrate, and pregelatinized starch;

[0027] The adhesive is selected from hydroxypropyl cellulose or povidone K30;

[0028] The disintegrant is selected from cross-linked carboxymethyl cellulose sodium or cross-linked polyvinylpyrrolidone;

[0029] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0030] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0031] The filler is selected from microcrystalline cellulose / lactose monohydrate or microcrystalline cellulose / pregelatinized starch;

[0032] The adhesive is povidone K30 or hydroxypropyl cellulose;

[0033] The disintegrant is cross-linked carboxymethyl cellulose sodium;

[0034] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0035] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant,

[0036] The filler is selected from microcrystalline cellulose / lactose monohydrate or microcrystalline cellulose / pregelatinized starch;

[0037] The adhesive is povidone K30;

[0038] The disintegrant is cross-linked carboxymethyl cellulose sodium.

[0039] In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant.

[0040] The filler is selected from microcrystalline cellulose PH101 / lactose monohydrate or microcrystalline cellulose PH101 / pregelatinized starch;

[0041] The adhesive is povidone K30;

[0042] The disintegrant is cross-linked carboxymethyl cellulose sodium;

[0043] The lubricant is magnesium stearate; the glidant is silicon dioxide. In certain embodiments, the pharmaceutical composition comprises a compound of formula (I), a filler, a binder and a disintegrant, and optionally, further comprises a lubricant and / or a glidant.

[0044] And in terms of weight percentage, the weight ratio of each component is as follows:

[0045] In certain embodiments, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate, starch, and dextrin.

[0046] In certain embodiments, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, and anhydrous calcium hydrogen phosphate.

[0047] In certain embodiments, the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, and pregelatinized starch.

[0048] In certain embodiments, the filler is selected from one or more of microcrystalline cellulose PH101, lactose monohydrate, pregelatinized starch, and anhydrous calcium hydrogen phosphate.

[0049] In certain embodiments, the filler is selected from one or two of microcrystalline cellulose PH101, lactose monohydrate, and pregelatinized starch.

[0050] In certain embodiments, the weight percentage of the filler is selected from 30% to 70%.

[0051] In certain embodiments, the weight percentage of the filler is selected from 40% to 70%.

[0052] In certain embodiments, the weight percentage of the filler is selected from 50% to 65%.

[0053] In certain embodiments, the binder is selected from one or more of copovidone VA64, hydroxypropyl cellulose, povidone K30, sodium carboxymethyl cellulose, or hypromellose.

[0054] In certain embodiments, the binder is selected from one or more of hydroxypropyl cellulose, povidone K30, or hypromellose.

[0055] In certain embodiments, the binder is selected from one or more of copovidone VA64, hydroxypropyl cellulose, and povidone K30.

[0056] In certain embodiments, the binder is selected from copovidone VA64, hydroxypropyl cellulose, or povidone K30.

[0057] In certain embodiments, the binder is selected from hydroxypropyl cellulose or povidone K30.

[0058] In certain embodiments, the binder is povidone K30.

[0059] In certain embodiments, the weight percentage of the binder is selected from 1% to 5%.

[0060] In certain embodiments, the weight percentage of the binder is selected from 2% to 5%.

[0061] In certain embodiments, the weight percentage of the binder is selected from 2% to 4%.

[0062] In certain embodiments, the weight percentage of the binder is selected from 3% to 5%.

[0063] In certain embodiments, the disintegrant is selected from one or more of croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose, or crospovidone.

[0064] In certain embodiments, the disintegrant is selected from one or more of croscarmellose sodium, sodium starch glycolate, or cross-linked polyvinylpyrrolidone.

[0065] In certain embodiments, the disintegrant is selected from croscarmellose sodium, sodium starch glycolate, or crospovidone.

[0066] In certain embodiments, the disintegrant is selected from croscarmellose sodium or sodium starch glycolate.

[0067] In certain embodiments, the disintegrant is selected from croscarmellose sodium or crospovidone.

[0068] In certain embodiments, the disintegrant is croscarmellose sodium.

[0069] In certain embodiments, the weight percentage of the disintegrant is selected from 2% to 8%.

[0070] In certain embodiments, the weight percentage of the disintegrant is selected from 2% to 6%.

[0071] In certain embodiments, the weight percentage of the disintegrant is selected from 4% to 6%.

[0072] In certain embodiments, the disintegrant can be added at once or twice, internally and externally.

[0073] In certain embodiments, the disintegrant is added twice, and the weight ratio of the two additions is 5:1-1:3, for example, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3.

[0074] In certain embodiments, the disintegrant is added twice, and the weight ratio of the two additions is 2:1-1:2, for example, 2:1, 1:1, 1:2.

[0075] In certain embodiments, the lubricant is selected from one or more of magnesium stearate, stearic acid, sodium stearyl fumarate, and glyceryl behenate.

[0076] In certain embodiments, the lubricant is selected from one or more of magnesium stearate, stearic acid, and glyceryl behenate.

[0077] In certain embodiments, the lubricant is selected from one or more of magnesium stearate, stearic acid, and sodium stearyl fumarate.

[0078] In certain embodiments, the lubricant is selected from magnesium stearate or stearic acid.

[0079] In certain embodiments, the lubricant is magnesium stearate.

[0080] In certain embodiments, the weight percentage of the lubricant is selected from 0-3%.

[0081] In certain embodiments, the weight percentage of the lubricant is selected from 0.01% to 3%.

[0082] In certain embodiments, the weight percentage of the lubricant is selected from 0.5% to 3%.

[0083] In certain embodiments, the weight percentage of the lubricant is selected from 1% to 3%.

[0084] In certain embodiments, the weight percentage of the lubricant is selected from 1% to 2%.

[0085] In certain embodiments, the glidant is selected from silicon dioxide or talc.

[0086] In certain embodiments, the glidant is silicon dioxide.

[0087] In certain embodiments, the weight percentage of the glidant is selected from 0-4%.

[0088] In certain embodiments, the weight percentage of the glidant is selected from 0.01% to 4%.

[0089] In certain embodiments, the weight percentage of the glidant is selected from 0.5-4%.

[0090] In certain embodiments, the weight percentage of the glidant is selected from 0-3%.

[0091] In certain embodiments, the weight percentage of the glidant is selected from 0.5-3%.

[0092] In certain embodiments, the weight percentage of the glidant is selected from 0-2%.

[0093] In certain embodiments, the weight percentage of the glidant is selected from 0.5-2%.

[0094] In certain embodiments, the weight percentage of the glidant is selected from 0-1%.

[0095] In certain embodiments, the weight percentage of the glidant is selected from 0.01-1%.

[0096] In certain embodiments, the weight percentage of the glidant is selected from 0.5-1%.

[0097] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 20%-50% of a compound of formula (I), 50%-65% of a filler, 1%-5% of a binder, 2%-8% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant.

[0098] In certain embodiments, the pharmaceutical composition comprises, by weight, 20%-50% of a compound of formula (I), 50%-65% of a filler, 1%-5% of a binder, 2%-8% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant;

[0099] The filler is selected from one or two of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, and anhydrous calcium hydrogen phosphate;

[0100] The adhesive is selected from hydroxypropyl cellulose or povidone K30;

[0101] The disintegrant is selected from cross-linked carboxymethyl cellulose sodium or cross-linked polyvinylpyrrolidone;

[0102] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0103] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 20%-50% of a compound of formula (I), 40%-60% of a filler, 3%-5% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant;

[0104] The filler is selected from one or two of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, and anhydrous calcium hydrogen phosphate;

[0105] The adhesive is povidone K30;

[0106] The disintegrant is cross-linked carboxymethyl cellulose sodium;

[0107] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0108] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 20%-50% of a compound of formula (I), 50%-65% of a filler, 3%-5% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant;

[0109] The filler is selected from microcrystalline cellulose / lactose monohydrate, microcrystalline cellulose / pregelatinized starch or microcrystalline cellulose / anhydrous calcium hydrogen phosphate;

[0110] The adhesive is povidone K30;

[0111] The disintegrant is cross-linked carboxymethyl cellulose sodium;

[0112] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0113] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 20%-50% of a compound of formula (I), 50%-65% of a filler, 3%-5% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant;

[0114] The filler is selected from microcrystalline cellulose PH101 / lactose monohydrate, microcrystalline cellulose PH101 / pregelatinized starch or microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate;

[0115] The adhesive is povidone K30;

[0116] The disintegrant is cross-linked carboxymethyl cellulose sodium;

[0117] The lubricant is magnesium stearate; the glidant is silicon dioxide.

[0118] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 20%-40% of a compound of formula (I), 50%-60% of a filler, 3%-5% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant.

[0119] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 30%-40% of a compound of formula (I), 50%-60% of a filler, 3%-4% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant.

[0120] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 30%-40% of a compound of formula (I), 50%-60% of a filler, 3%-3.5% of a binder, 4%-6% of a disintegrant, 1%-3% of a lubricant, and 0.01-1% of a glidant.

[0121] In certain embodiments, the pharmaceutical composition comprises, by weight percentage, 30%-40% of a compound of formula (I), 50%-60% of a filler, 3%-3.5% of a binder, 4%-6% of a disintegrant, 1%-2% of a lubricant, and 0.01-1% of a glidant.

[0122] In certain embodiments, the filler is selected from one or two of microcrystalline cellulose, lactose monohydrate, and pregelatinized starch. In certain embodiments, the filler is selected from microcrystalline cellulose / lactose monohydrate, microcrystalline cellulose / pregelatinized starch, or microcrystalline cellulose / anhydrous calcium hydrogen phosphate.

[0123] In certain embodiments, the filler is selected from microcrystalline cellulose / lactose monohydrate, or microcrystalline cellulose / pregelatinized starch.

[0124] In certain embodiments, the weight ratio of microcrystalline cellulose / lactose monohydrate is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0125] In certain embodiments, the weight ratio of microcrystalline cellulose / pregelatinized starch is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0126] In certain embodiments, the weight ratio of microcrystalline cellulose / anhydrous calcium hydrogen phosphate is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0127] In certain embodiments, the filler is selected from microcrystalline cellulose PH101 / lactose monohydrate, microcrystalline cellulose PH101 / pregelatinized starch, or microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate.

[0128] In certain embodiments, the filler is selected from microcrystalline cellulose PH101 / lactose monohydrate, or microcrystalline cellulose PH101 / pregelatinized starch.

[0129] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / lactose monohydrate is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0130] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / pregelatinized starch is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0131] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate is selected from 7:1-1:2, such as 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2.

[0132] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / lactose monohydrate is selected from 5:1 to 1:1.

[0133] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / pregelatinized starch is selected from 5:1 to 1:1.

[0134] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate is selected from 5:1 to 1:1.

[0135] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / lactose monohydrate is selected from 4:1 to 1:1.

[0136] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / pregelatinized starch is selected from 5:1-2:1.

[0137] In certain embodiments, the weight ratio of microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate is selected from 4:1 to 1:1.

[0138] In certain embodiments, the disintegrant is croscarmellose sodium.

[0139] In certain embodiments, the disintegrant can be added at once or twice, internally and externally.

[0140] In certain embodiments, the disintegrant is added twice, and the weight ratio of the two additions is 5:1-1:3, for example, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3.

[0141] In certain embodiments, the disintegrant is added twice, and the weight ratio of the two additions is 2:1-1:2, for example, 2:1, 1:1, 1:2.

[0142] In certain embodiments, the disintegrant is added twice, and the weight ratio of the two additions is 1:1.

[0143] In certain embodiments, the lubricant is present in an amount of 1% by weight.

[0144] In certain embodiments, the weight percentage of the glidant is 0.5%.

[0145] In certain embodiments, the composition optionally comprises an appropriate amount of a wetting agent selected from anhydrous ethanol or water.

[0146] In certain embodiments, the composition optionally comprises a suitable amount of a wetting agent, which is water.

[0147] In certain embodiments, the pharmaceutical composition can be prepared as a tablet or capsule.

[0148] On the other hand, the present invention also provides a method for preparing tablets of the pharmaceutical composition as described above, comprising the following steps:

[0149] (1) mixing the compound of formula (I) with a filler and an internal disintegrant to obtain a premix;

[0150] (2) preparing adhesive solution;

[0151] (3) mixing the binder solution obtained in step (2) with the premix of step (1) and granulating;

[0152] (4) drying the granules obtained in step (3) and performing dry granulation;

[0153] (5) mixing the granules obtained after dry granulation in step (4) with an external disintegrant, an optional lubricant, and an optional glidant to obtain a final mixture;

[0154] (6) compressing the final mixture obtained in step (5) to obtain a tablet core;

[0155] (7) coating the tablet core obtained in step (6).

[0156] In certain embodiments, anhydrous ethanol or water is used as a wetting agent when preparing the adhesive solution.

[0157] In certain embodiments, water is used as a wetting agent when preparing the adhesive solution.

[0158] In certain embodiments, the coating powder used in the coating process is selected from a gastric-soluble film coating premix, and the coating weight gain is 2%-8%, preferably, the coating weight gain is 2%-6%.

[0159] In certain embodiments, the coating dispersant used in the coating process is selected from anhydrous ethanol or water.

[0160] In certain embodiments, the coating dispersant used in the coating process is water.

[0161] In another aspect, the present invention also relates to use of the aforementioned pharmaceutical composition in the preparation of a medicament for preventing and / or treating cancer-related diseases mediated by CDK4 / 6 kinase in a subject.

[0162] The present invention also provides a method for treating and / or preventing cancer-related diseases mediated by CDK4 / 6 kinase in a mammal in need thereof, comprising administering a therapeutically and / or preventively effective amount of the pharmaceutical composition of the present invention to the mammal in need thereof.

[0163] In certain embodiments, the CDK4 / 6 kinase-mediated cancer-related disease is selected from the group consisting of brain tumors, lung cancer, squamous cell carcinoma, bladder cancer, gastric cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, rectal cancer, liver cancer, kidney cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, prostate cancer, female reproductive tract cancer, carcinoma in situ, lymphoma, neurofibroma, thyroid cancer, bone cancer, skin cancer, brain cancer, colon cancer, testicular cancer, gastrointestinal stromal tumor, prostate tumor, mast cell tumor, multiple myeloma, melanoma, glioma, and sarcoma.

[0164] In another aspect, the present invention also provides a kit comprising:

[0165] (a) the aforementioned pharmaceutical composition,

[0166] and (b) an effective amount of one or more anticancer agents.

[0167] Explanation of terms

[0168] In the present invention, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. However, for a better understanding of the present invention, definitions of some terms are provided below. In the event that the definitions and explanations of terms provided herein are inconsistent with the meanings commonly understood by those skilled in the art, the definitions and explanations of the terms provided herein shall prevail.

[0169] The fillers described in the present invention include but are not limited to microcrystalline cellulose, lactose monohydrate, pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate, starch, and dextrin.

[0170] The adhesives described in the present invention include but are not limited to copovidone VA64, hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, povidone K30, copovidone, maltodextrin, and maltose.

[0171] The wetting agent described herein refers to a solvent used to prepare the adhesive solution, which is gradually removed during the preparation of the pharmaceutical composition. Examples include, but are not limited to, 90% or greater ethanol and water. Specific examples include, but are not limited to, 90% ethanol, 95% ethanol, anhydrous ethanol, and water.

[0172] The "appropriate amount" in the "appropriate amount of wetting agent" described in the present invention means adjusting the amount of the wetting agent according to the amount of the adhesive, which is mainly determined based on the percentage of the adhesive dosage (in the prescription) and the mass fraction of the adhesive. The commonly used mass fraction of the adhesive (mass ratio to the wetting agent) is selected from 2%-10% (w / w), including but not limited to 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% and 10%.

[0173] The disintegrants described in the present invention include but are not limited to cross-linked sodium carboxymethyl cellulose, hydroxymethyl cellulose, hydroxymethyl cellulose calcium, low-substituted hydroxypropyl methyl cellulose, cross-linked polyvinylpyrrolidone, sodium hydroxymethyl starch, and hydroxypropyl starch.

[0174] The lubricant of the present invention includes but is not limited to magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, glyceryl behenate, hydrogenated vegetable oil, polyethylene glycol, and magnesium lauryl sulfate.

[0175] The glidant of the present invention includes but is not limited to talc, micro-powder silica gel, and silicon dioxide.

[0176] The dispersant of the present invention refers to a solvent used to dissolve the coating powder, which is gradually removed during the tablet coating process. The dispersant includes but is not limited to anhydrous ethanol and water.

[0177] The pharmaceutical composition of the present invention can be packaged in any packaging that does not affect the stability of the pharmaceutical preparation. For example, the inner packaging can be PVC aluminum-plastic blister packaging, double aluminum packaging, PVDC aluminum-plastic blister packaging, etc., and the outer packaging can be a composite film bag.

[0178] The term "effective amount" as used herein refers to a dosage of a drug that can prevent, alleviate, delay, inhibit, or cure a condition in a subject. The dosage depends on the route of administration, the pharmacokinetics of the drug, the severity of the condition, and the subject's individual characteristics (gender, weight, height, age).

[0179] The term "microcrystalline cellulose / lactose monohydrate" as used herein refers to a mixture of microcrystalline cellulose and lactose monohydrate in any possible ratio, including but not limited to 100:1-1:100, 10:1-1:10, 7:1-1:2, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, and 1:4. Both microcrystalline cellulose and lactose monohydrate include various product types for industrial use. The terms "microcrystalline cellulose / pregelatinized starch" and "microcrystalline cellulose / anhydrous calcium hydrogen phosphate" as used herein are as defined above.

[0180] In the pharmaceutical composition of the present invention, the sum of the weight percentages of its components is less than or equal to 100%.

[0181] Advantageous Effects of the Invention

[0182] 1. The pharmaceutical composition of the present invention has good disintegration and dissolution properties.

[0183] 2. The pharmaceutical composition of the present invention is stable in nature and can provide a long shelf life.

[0184] 3. The pharmaceutical composition of the present invention has stable process, controllable cost, strong repeatability, and can meet the requirements of industrial production. Specific implementation plan

[0185] The technical solutions of the present invention will be described below in conjunction with specific embodiments, and the above contents of the present invention will be further described in detail. However, this should not be understood as limiting the scope of the above subject matter of the present invention to the following embodiments. All technologies implemented based on the above contents of the present invention fall within the scope of the present invention.

[0186] The compounds of formula (I) used in the following examples or experimental examples can be prepared by referring to the methods of the prior art.

[0187] It should be noted that in the following examples, when the formulation compositions are identical, they are assigned the same formulation number. However, because production batches may vary, for formulations with the same formulation number, slight differences in basic properties, dissolution rate, particle size distribution, and other data of the granules may occur between different examples. Those skilled in the art will understand that such differences are normal errors in the experimental process.

[0188] Example 1: Investigation of filler types

[0189] 1. Preparation process:

[0190] 1) Weighing: Weigh the compound of formula (I), filler, internal disintegrant and other internal raw materials and auxiliary materials according to the required amount and set aside;

[0191] 2) Mixing: Place the weighed raw materials and auxiliary materials in a wet granulator and mix them evenly;

[0192] 3) Preparation of adhesive solution: Weigh the adhesive according to the required amount and prepare the adhesive solution using water as the wetting agent;

[0193] 4) Granulation, wet granulation: add the prepared binder solution to the raw materials mixed in step (2), adjust the granulator to appropriate parameters, and granulate;

[0194] 5) Drying and dry granulation: The obtained wet granules are dried in a fluidized bed granulator and dry granulated;

[0195] 6) Adding excipients and mixing: adding disintegrants, lubricants and glidants according to the particle yield to obtain the final mixture;

[0196] 7) Tableting: Compressing the final mixture obtained in step (6) on a tablet press to obtain tablet cores;

[0197] 8) Coating the tablet cores obtained in step (7) (coating powder is selected from gastric soluble film coating premix, coating weight gain 2%-8%).

[0198] 2. Prescription design

[0199] Table 1 Prescription design for filler screening

[0200] Table 2 Prescription design for filler screening

[0201] 3. Investigation results

[0202] Table 3 Filler screening results

[0203] Table 4 Filler screening results

[0204] Table 5 Results of investigation on filler type selection - related substances and contents

[0205] 4. Conclusions of the investigation:

[0206] As can be seen from the results in Table 3, except for the combination of microcrystalline cellulose PH101 and pregelatinized starch (2:1), the formulations with the combination of microcrystalline cellulose PH101 and mannitol (2:1) or the combination of mannitol and pregelatinized starch (2:1) as fillers all showed sticking and disintegration phenomena. Moreover, the formulation with the combination of microcrystalline cellulose PH101 and pregelatinized starch (2:1) as fillers was superior to the other formulations in soft material properties, whether it sticks to the screen, and disintegration time, and there were no significant differences in other key assessment results.

[0207] From the results in Tables 4 and 5, it can be seen that the soft material prepared by the combination of microcrystalline cellulose PH101 / mannitol (4:1) is slightly wet, and the wet granules are easily squeezed into agglomerates; the soft materials, wet granules, and dry granules prepared by the combinations of microcrystalline cellulose PH101 / lactose monohydrate (4:1), microcrystalline cellulose PH101 / anhydrous calcium hydrogen phosphate (4:1), and microcrystalline cellulose PH101 / pregelatinized starch (4:1) all have good properties; in addition, the four filler combinations of Formulations 4 to 7 did not cause sticking, and there was no significant difference in the related substances and their stability.

[0208] Example 2: Filler Type Selection

[0209] The types of fillers were investigated, focusing on the impact of filler types on the key quality attribute, dissolution.

[0210] 1. Preparation process

[0211] According to the prescription, the preparation process of Example 1 was followed to prepare the product.

[0212] 2. Prescription design

[0213] Table 6 Filler type selection - prescription design

[0214] 3. Investigation results

[0215] Table 7 Results of investigation on filler type selection - dissolution

[0216] 4. Conclusion

[0217] The results show that the combination of microcrystalline cellulose and lactose monohydrate dissolves quickly and completely, the combination of microcrystalline cellulose and anhydrous calcium hydrogen phosphate dissolves slowly and incompletely, and the combination of pregelatinized starch and mannitol dissolves relatively slowly.

[0218] Example 3: Investigation of filler dosage and ratio

[0219] 1. Preparation process

[0220] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0221] 2. Prescription design

[0222] Table 8 Prescription design of filler dosage

[0223] Table 9 Prescription design of filler dosage

[0224] 3. Investigation results

[0225] Table 10 Results of optimization study on filler dosage

[0226] Table 11 Results of filler dosage optimization - particle size distribution

[0227] Table 12 Results of optimization study on filler dosage

[0228] Table 13 Results of filler dosage optimization study - dissolution

[0229] 4. Conclusion

[0230] From the above test results, it can be seen that different dosages of microcrystalline cellulose PH101 and pregelatinized starch (2:1, 3:1, 5:1) have no obvious effect on whether it is sticky, particle ratio, dissolution rate, etc.

[0231] Adjusting the ratio of microcrystalline cellulose PH101 to lactose monohydrate from 4:1 to 2:1 or 1:1 had no significant effect on the particle size, compactness, tablet friability, disintegration and dissolution of the dry granules.

[0232] Example 4: Selection of adhesive types

[0233] 1. Preparation process

[0234] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0235] 2. Prescription design

[0236] Table 14 Adhesive type selection-prescription design

[0237] 3. Investigation results

[0238] Table 15 Results of adhesive selection investigation - basic items for tablets

[0239] Table 16 Results of adhesive selection investigation - basic items for tablets

[0240] 4. Conclusion

[0241] The above results indicate that using copolyvidone VA64 as a binder produces softer granules with more fine powder, which can easily break during tableting. This increases the risk of powder leakage and excessive fine powder can lead to tableting difficulties. Using povidone K30 or hydroxypropyl cellulose as a binder, however, produces granules with greater strength than copolyvidone VA64. There were no significant differences among the three binders in other key indicators, such as dissolution profiles and stability.

[0242] Example 5: Adhesive Type Selection

[0243] 1. Preparation process

[0244] According to the prescription, the preparation process of Example 1 was followed to prepare the product.

[0245] 2. Prescription design

[0246] Table 17 Adhesive type selection - prescription design

[0247] 3. Investigation results

[0248] Table 18 Results of adhesive type selection investigation - basic items

[0249] Table 19 Results of adhesive type selection investigation - dissolution

[0250] 4. Conclusion

[0251] The results of the investigation show that the properties of the soft material, wet granules and dry granules prepared by using methyl cellulose or sodium carboxymethyl cellulose as binders are inferior to those of povidone K30. In addition, the disintegration time of tablets prepared with methyl cellulose as a binder is slightly delayed, and the dissolution is slow and incomplete. The disintegration time of tablets prepared with sodium carboxymethyl cellulose as a binder is significantly delayed, and the dissolution is slow.

[0252] Based on the results of Examples 4 and 5, selecting povidone K30 or hydroxypropyl cellulose with appropriate viscosity can not only improve the compactness of the granules and ensure the normal and efficient tableting process, but also ensure that the tablets can be quickly and completely dissolved.

[0253] Example 6: Investigation on Optimization of Adhesive Dosage

[0254] 1. Preparation process

[0255] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0256] 2. Prescription design

[0257] Table 20 Adhesive dosage optimization - prescription design

[0258] 3. Investigation results

[0259] Table 21 Results of optimization study on adhesive dosage - basic items of tablets

[0260] Table 22 Results of adhesive dosage optimization study - dissolution

[0261] 4. Conclusion

[0262] There was no sticking tendency when the binder dosage was 4%, 3.5% and 3%. There was no significant difference in tablet hardness, disintegration time and dissolution among the three dosages.

[0263] Example 7: Selection of disintegrant type

[0264] 1. Preparation process

[0265] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0266] 2. Prescription design

[0267] Table 23 Disintegrant type selection - prescription design

[0268] 3. Investigation results

[0269] Table 24 Results of investigation on the selection of disintegrant types - basic items for tablets

[0270] Table 25 Disintegrant Type Selection Investigation Results - Dissolution

[0271] 4. Conclusion

[0272] From the above data, it can be seen that under the condition of comparable hardness, cross-linked carboxymethyl cellulose sodium as a disintegrant is significantly superior to cross-linked polyvinylpyrrolidone XL-10 as a disintegrant in terms of disintegration time, dissolution rate and dissolution stability.

[0273] Example 8: Selection of disintegrant type

[0274] 1. Preparation process

[0275] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0276] 2. Prescription design

[0277] Table 26 Disintegrant Type Selection - Formulation Design

[0278] 3. Investigation results

[0279] Table 27 Results of the selection of disintegrant types - basic items

[0280] Table 28 Disintegrant Type Selection Results - 120mg Dissolution

[0281] 4. Conclusion

[0282] The results of the investigation show that the tablets prepared with low-substituted hydroxypropyl cellulose as a disintegrant dissolve slowly and incompletely, and the tablets prepared with sodium carboxymethyl starch as a disintegrant dissolve slowly. The disintegration effects of both are inferior to that of cross-linked sodium carboxymethyl cellulose.

[0283] Example 9: Investigation of disintegrant dosage

[0284] 1. Preparation process

[0285] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0286] 2. Prescription design

[0287] Table 29 Disintegrant dosage investigation - prescription design

[0288] 3. Investigation results

[0289] Table 30 Results of Disintegrant Dosage Optimization - Basic Tablet Items

[0290] Table 31 Disintegrant dosage optimization results - dissolution

[0291] 4. Conclusion

[0292] The optimal method for using croscarmellose sodium as a disintegrant is to combine it with granules and internal and external disintegrants. When the disintegrant dosages were 3% each, 2% each, and 1% each, respectively, while maintaining consistent tablet hardness, formulations with different disintegrant ratios showed slight differences in disintegration times, but had little impact on the overall dissolution profile.

[0293] Example 10: Selection of lubricant / glidant type

[0294] In order to solve the problem of easy sticking during tableting and ensure the normal progress of the production process, the types of lubricants are screened.

[0295] 1. Preparation process

[0296] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0297] 2. Prescription design

[0298] Table 32 Lubricant / glidant type selection - prescription design

[0299] 3. Investigation results

[0300] Table 33 Lubricant / glidant type selection - sticking situation

[0301] 4. Conclusion

[0302] The results of the investigation show that when sodium stearyl fumarate is selected as the lubricant, obvious sticking phenomenon occurs, while when magnesium stearate is selected as the lubricant, no sticking phenomenon occurs, which ensures the smooth progress of the tableting process.

[0303] Example 11: Lubricant dosage investigation

[0304] 1. Preparation process

[0305] According to the prescription, the preparation process of Example 1 was followed to prepare the

[0306] 2. Prescription design

[0307] Table 34 Lubricant dosage investigation-prescription design

[0308] 3. Investigation results

[0309] Table 35 Lubricant dosage optimization results - particle size distribution

[0310] Table 36 Results of Lubricant Dosage Optimization - Tablet Basic Items

[0311] 4. Conclusion

[0312] The experiment shows that when the particle size, properties and tablet hardness are basically controlled, the tablet surface smoothness of the tablets prepared with a 0.5% magnesium stearate formula decreases and there is a risk of sticking; the tablets prepared with a 1% magnesium stearate formula have no sticking tendency and can meet the quality standard requirements.

Claims

1. A pharmaceutical composition comprising a compound of formula (I), a filler, a binder and a disintegrant, and optionally, a lubricant and / or a glidant, Preferably, in terms of weight percentage, the weight ratios of the components are as follows:

2. The pharmaceutical composition according to claim 1, wherein the filler is selected from one or more of microcrystalline cellulose, lactose monohydrate, pregelatinized starch, mannitol, anhydrous calcium hydrogen phosphate, starch, and dextrin; preferably, the weight percentage of the filler is selected from 30%-70%, more preferably 50%-65%.

3. The pharmaceutical composition according to any one of claims 1 to 2, wherein the binder is selected from one or more of povidone VA64, hydroxypropyl cellulose, povidone K30, sodium carboxymethyl cellulose or hypromellose; preferably, the weight percentage of the binder is selected from 1% to 5%.

4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate, low-substituted hydroxypropyl cellulose, or cross-linked polyvinylpyrrolidone; preferably, the disintegrant is added in two doses; more preferably, the weight ratio of the two additions of the disintegrant is 5:1-1:3, preferably 2:1-1:

2.

5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the lubricant is selected from one or more of magnesium stearate, stearic acid, sodium stearyl fumarate, and glyceryl behenate; preferably, the weight percentage of the lubricant is selected from 0-3%, more preferably 1%-3%.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the glidant is selected from silicon dioxide or talc; preferably, the weight percentage of the glidant is selected from 0-3%, more preferably 0-1%.

7. The pharmaceutical composition of claim 1, comprising, by weight, 20%-50% of a compound of formula (I), 50%-65% of a filler, 1%-5% of a binder, 2%-8% of a disintegrant, 1%-3% of a lubricant, and 0-1% of a glidant; Preferably, the filler is selected from microcrystalline cellulose, lactose monohydrate, pregelatinized starch, anhydrous calcium hydrogen phosphate One or two; The adhesive is selected from hydroxypropyl cellulose or povidone K30; The disintegrant is selected from cross-linked carboxymethyl cellulose sodium or cross-linked polyvinylpyrrolidone; The lubricant is magnesium stearate; the glidant is silicon dioxide.

8. The pharmaceutical composition according to claim 7, wherein the filler is selected from microcrystalline cellulose / lactose monohydrate, microcrystalline cellulose / pregelatinized starch, or microcrystalline cellulose / anhydrous calcium hydrogen phosphate. Preferably, the weight ratio of microcrystalline cellulose / lactose monohydrate is selected from 7:1-1:2, the weight ratio of microcrystalline cellulose / pregelatinized starch is selected from 7:1-1:2, and the weight ratio of microcrystalline cellulose / anhydrous calcium hydrogen phosphate is selected from 7:1-1:

2.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein The pharmaceutical composition is prepared into tablets or capsules.

10. A method for preparing tablets of the pharmaceutical composition according to any one of claims 1 to 9, characterized in that: The following steps are involved: (1) mixing the compound of formula (I) with a filler and an internal disintegrant to obtain a premix; (2) preparing adhesive solution; (3) mixing the binder solution obtained in step (2) with the premix of step (1) and granulating; (4) drying the granules obtained in step (3) and performing dry granulation; (5) mixing the granules obtained after dry granulation in step (4) with an external disintegrant, an optional lubricant, and an optional glidant to obtain a final mixture; (6) compressing the final mixture obtained in step (5) to obtain a tablet core; (7) coating the tablet core obtained in step (6).